We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) entered a research and development collaboration with Japan-based biopharmaceutical company, Carna Biosciences Inc.
Both the companies have collaborated to develop and commercialize small molecule compounds in immuno-oncology.
The deal will also allow Gilead to access Carna’s proprietary lipid kinase drug discovery platform. Per the terms, the company will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Carna.
In exchange, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in milestone payments. Carna will also receive royalties on future net sales.
Gilead is currently making efforts to build a pipeline in immuno-oncology. In December 2018, it collaborated with Agenus (AGEN - Free Report) for the development and commercialization of up to five novel immuno-oncology therapies.
Gilead’s stock has gained 9.5% in the year so far compared with the industry's growth of 4.2%.
Recently, the company collaborated with San Francisco-based Nurix Therapeutics, Inc. to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
Earlier, Gilead also collaborated with Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases.
Given the persistent decline in HCV sales, stiff competition from the likes of Glaxo (GSK - Free Report) and pricing pressure in the HIV market, the company is looking to newer avenues to boost the top line. Gilead has made quite a few collaborations, of late, to strengthen and diversify its pipeline.
The company is intending to foray into the inflammation market with late-stage candidate, filgotinib. It has collaborated with big pharma companies like Novo Nordisk (NVO - Free Report) to develop treatments for non-alcoholic steatohepatitis (NASH).
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
Gilead Sciences, Inc. (GILD - Free Report) entered a research and development collaboration with Japan-based biopharmaceutical company, Carna Biosciences Inc.
Both the companies have collaborated to develop and commercialize small molecule compounds in immuno-oncology.
The deal will also allow Gilead to access Carna’s proprietary lipid kinase drug discovery platform. Per the terms, the company will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Carna.
In exchange, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in milestone payments. Carna will also receive royalties on future net sales.
Gilead is currently making efforts to build a pipeline in immuno-oncology. In December 2018, it collaborated with Agenus (AGEN - Free Report) for the development and commercialization of up to five novel immuno-oncology therapies.
Gilead’s stock has gained 9.5% in the year so far compared with the industry's growth of 4.2%.
Recently, the company collaborated with San Francisco-based Nurix Therapeutics, Inc. to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
Earlier, Gilead also collaborated with Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases.
Given the persistent decline in HCV sales, stiff competition from the likes of Glaxo (GSK - Free Report) and pricing pressure in the HIV market, the company is looking to newer avenues to boost the top line. Gilead has made quite a few collaborations, of late, to strengthen and diversify its pipeline.
The company is intending to foray into the inflammation market with late-stage candidate, filgotinib. It has collaborated with big pharma companies like Novo Nordisk (NVO - Free Report) to develop treatments for non-alcoholic steatohepatitis (NASH).
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>